Navigation Links
Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row

TARRYTOWN, N.Y., Oct. 24, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #1 employer in the global biopharmaceutical industry in the journal's annual Top Employers Survey for the second year in a row.  This distinction will be celebrated Monday, October 28, in conjunction with a groundbreaking ceremony for two new buildings to be constructed at the Regeneron campus in Westchester County, New York.

U.S. Senator Charles E. Schumer, U.S. Rep. Nita Lowey, Empire State Development Corp. President & CEO Kenneth Adams, and other public officials are scheduled to participate in an event with Regeneron employees that will celebrate the biotechnology company's latest expansion and the emergence of the lower Hudson Valley as a life sciences cluster.

"Regeneron's tremendous growth and our current expansion plans are undoubtedly thanks to our employees.  If we are the best place to work, it is because we have the best employees and a culture where they feel empowered and challenged," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.
George D. Yancopoulos, Chief Scientific Officer and President, Regeneron Laboratories, said,  "As we are a company founded on scientific excellence, it is very meaningful to us to be recognized by Science magazine two consecutive years now as the top place to work in the industry." 

The new facilities, for which site preparation is underway, will include a total of 300,000 square feet of laboratory and office space, with a projected move-in date of third quarter 2015.  The expansion will increase Regeneron's square footage on the campus by more than 40 percent and make it possible for Regeneron to create approximately 400 new full-time jobs in Westchester, where it currently employs more than 1,500.  With a total of over 2,200 employees, including nearly 700 in the Regeneron Industrial Operations and Product Supply group in Rensselaer, New York near Albany, Regeneron is the largest biotechnology company in New York State and one of the five largest in the world by market capitalization.

The 2013 Science survey sought to identify the companies with the best reputations as employers, based on 3,656 survey responses from readers of Science and other survey invitees.  Survey participants came from North America (81%), Europe (10%), and Asia/Pacific Rim (7%); over 80% worked in private industry.  Details of the rankings and survey results can be found in and will be featured in the October 25, 2013 print issue. 

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis.  For additional information about the company, please visit Information:Manisha Narasimhan, Ph.D.Peter DworkinInvestor RelationsCorporate

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
2. Regeneron Announces March 2012 Investor Conference Presentations
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
5. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
8. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
9. Callibra, Inc. dba Discharge 1-2-3 is Named Winner of 2011 Chicago Innovation Award
10. Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual Stevie® Awards for Women in Business
11. Sequenom Named to NASDAQ Global Select Market
Post Your Comments:
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is ... it is bound to proteins, copper is also toxic to cells. With a ... Polytechnic Institute (WPI) will conduct a systematic study of copper in the bacteria ...
(Date:11/24/2015)... ... , ... This fall, global software solutions leader SAP and AdVenture Capital brought ... pitch their BIG ideas to improve health and wellness in their schools. , Now, ... the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl 50, ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):